Latest Interviews
Showing 1–3 of 3 transcripts.
Clear all filters- a16z10 min
Disrupt Yourself
The speaker frames the current transition in life sciences as an industrial revolution where biology shifts from artisanal discovery to engineered automation, urging leaders to proactively disrupt themselves before market forces do. Drawing parallels to strategic pivots by Jensen Huang at Nvidia and Steve Jobs with AT&T, the presentation defines corporate survival as a form of social engineering that prioritizes future ecosystems over existing profitability. Ultimately, the event calls for redefining healthcare and entertainment as technology sectors to fundamentally reshape illness prevention and treatment.
- a16z21 min
AI is Industrializing Discovery
The speaker characterizes the current biotech era as an industrial revolution where AI is transforming drug discovery from a bespoke artisanal model into a scalable, engineering-driven process. By overcoming myths regarding biological complexity and data scarcity through techniques like graph convolutions and one-shot learning, companies are achieving accuracy rates of over 90% in biomarker discovery and predicting clinical outcomes with modest incremental gains. This strategic shift promises to slash manufacturing costs for protein therapeutics by up to 90% and reduce trial expenses, creating a critical opportunity for professionals to merge domain expertise with AI skills to industrialize discovery at unprecedented scale.
- a16z59 min
a16z Podcast | The Science and Business of Innovative Medicines
Jorge Conde, Vijay Pande, Sonal Chokshi, Vas Narasimhan
Novartis transformed its portfolio through a $50 billion restructuring that divested consumer healthcare to prioritize advanced therapies, data science, and proprietary platforms for cell and gene treatments. Under CEO Vas Narasimhan, the company enforces strict "standard of care" mandates for project approval, integrates market access early in development, and invested $15 billion to own specialized infrastructure while leveraging AI for financial forecasting and pathology analysis. This strategic pivot targets a 10% clinical success rate by shifting from bespoke drug development to modular platforms and dedicated digital innovation centers, positioning the firm to address undruggable targets and future modalities like xenotransplantation.